CalciMedica initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis initiated coverage of CalciMedica with a Buy rating and $20 price target. CalciMedica is focusing on developing first-in-class therapies for inflammatory diseases with high unmet need, the analyst tells investors in a research note. Backed by strong preclinical data and now translating to positive clinical data, the company’s lead asset Auxora is being developed for several acute inflammatory indications, says the firm.